GET DAILY SIGNALSenGene Therapeutics (ENGN): Analyst Target of $3.30 Implies +113% Upside
Key Takeaways
- The central $3.30 stock price target is the arithmetic mean of roughly seven current analyst price targets, which range from $2.00 to $5.00.
- With enGene Therapeutics (Nasdaq: ENGN) trading near $1.55, reaching $3.30 would require a gain of roughly 113%, a very large move.
- Bullish analysts (H.C. Wainwright and Raymond James at $4) see value in the drug's safety profile, while more cautious firms (Wells Fargo, UBS, and Leerink at $2) stress durability concerns.
- The stock fell about 80% in May 2026 after interim Phase 2 LEGEND data showed weaker-than-expected durability of response in bladder cancer.
- The biggest risk is that detalimogene's durability trails competitors, clouding its commercial and regulatory path.
- For more detail on this ticker, explore the Major News, Today's Price Move, Forecast, and Earnings pages.
- Investors can also explore Trending AI Robots for AI-driven market analysis tools.
Analyst Price Targets and Consensus View
The central $3.30 target reflects current sell-side research rather than a single opinion. Data from S&P Global show nine analysts covering ENGN, with an average one-year target of about $3.29 and a range spanning $2.00 to $5.00. Verified individual targets include H.C. Wainwright ($4, Buy) and Piper Sandler ($4, Hold) from mid-October 2026, Wells Fargo ($2, Hold), UBS ($2, Hold), and Leerink Partners ($2, Hold) from September and early October 2026, plus Raymond James ($4, Buy). Two additional firms, Morgan Stanley and Guggenheim, maintain ratings without published price targets. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Views split sharply along durability expectations. After the May 2026 data release, Wells Fargo cut its target from $25 to $2 and downgraded the stock to Equal Weight; Piper Sandler moved to Neutral and lowered its target from $7 to $4; Guggenheim shifted from Buy to Neutral; and H.C. Wainwright kept a Buy rating while slashing its target from $25 to $6, later to $4. The wide $2.00-to-$5.00 range reflects genuine disagreement about whether detalimogene can remain commercially competitive.
Current Market Position and Path Toward the Target
enGene Therapeutics Inc. is a Montreal-based clinical-stage biotechnology company developing genetic medicines, led by detalimogene voraplasmid for non-muscle invasive bladder cancer (NMIBC). The company is pre-revenue, with a market capitalization near $104 million and cash of roughly $266 million as of its latest quarter.
ENGN trades near $1.55, at the low end of a 52-week range of $1.40 to $12.25. Reaching the $3.30 target implies upside of about 113%, which qualifies as a very large move. The path would likely require stabilization of efficacy trends, a favorable FDA engagement, and renewed confidence that a potential biologics license application remains viable. From what I see, the current valuation leaves little room for error.
What Could Support a Move Toward the Target
Several factors underpin the more constructive targets. Detalimogene demonstrated a favorable safety and tolerability profile, with mostly mild treatment-related adverse events and a low 3.2% progression rate to muscle-invasive disease. The company holds RMAT and Fast Track designations, and management plans further FDA engagement and additional LEGEND data in the second half of 2026. Its non-viral DDX delivery platform also offers practical advantages such as intravesical administration without cold-chain storage. With cash exceeding its market value, ENGN retains runway to generate more mature data.
What Could Prevent the Target From Being Reached
The principal obstacle is durability. The 12-month complete response rate of 25% (by Kaplan-Meier estimate) and weaker trends in recent patient cohorts trailed competitors such as Anktiva, cretostimogene, and Adstiladrin. Analysts have questioned whether detalimogene can close the efficacy gap, with one projection cutting peak sales estimates by roughly 65%. A shareholder-rights investigation, ongoing net losses, pre-revenue status, and the risk that regulators decline to accept a filing all represent additional headwinds. Valuation compression in a crowded NMIBC field could keep the stock well below $3.30.
Technical Levels and Market Structure
Technically, ENGN remains in a deep downtrend, trading far below its prior highs and under major moving averages. The 52-week low near $1.40 acts as a key support level, while $2.00 and $4.00 — which coincide with the cluster of current analyst targets — represent important psychological and resistance levels. A sustained move above $2.00 would be an early sign of stabilization, while $4.00 marks the upper boundary of most current forecasts. I’m watching this closely for any signs of stabilization.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a roughly 12-month research horizon, though individual assumptions vary. Near-term catalysts include fuller LEGEND follow-up data, the outcome of FDA engagement expected in the second half of 2026, and the company's next earnings report, estimated for late December 2026. Investors should watch analyst revisions, cohort consistency, and any regulatory or financing developments, as these will most directly shape whether the $3.30 target remains attainable.
Using AI Daily Buy/Sell Signals for Volatile Names
In my research process, Tickeron's AI Daily Buy/Sell Signals help monitor momentum on names like ENGN by generating Buy, Sell, or Hold signals based on changing market conditions and technical behavior. For a volatile stock, these tools can surface opportunities and detect shifting trends more efficiently than manual review alone. Traders seeking a data-driven edge may find it worthwhile to explore these signals as part of a broader research process.
Final Assessment
The question of whether ENGN can reach $3.30 ultimately hinges on detalimogene's durability data and the company's regulatory path. The target is the average of current analyst price targets spanning $2.00 to $5.00, implying a roughly 113% move from today's level — a very large gap that reflects genuine uncertainty. Supportive factors include the drug's safety profile, low progression rate, regulatory designations, and a cash position exceeding the market cap. Against these stand weaker durability versus competitors, analyst downgrades, a shareholder investigation, and pre-revenue status. The wide analyst range signals that no consensus exists on the stock's fate, and investors should focus on upcoming FDA engagement and full LEGEND data before drawing conclusions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ENGN's Stochastic Oscillator is remaining in oversold zone for 14 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ENGN's RSI Indicator exited the oversold zone, 20 of 23 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
Following a +2.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where ENGN advanced for three days, in 124 of 145 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
ENGN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ENGN as a result. In 40 of 52 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 77%.
The Moving Average Convergence Divergence Histogram (MACD) for ENGN turned negative on October 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 26 similar instances when the indicator turned negative. In 23 of the 26 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
ENGN moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ENGN crossed bearishly below the 50-day moving average on October 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 5 of 9 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 56%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ENGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for ENGN entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 40 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.451) is normal, around the industry mean (3.037). P/E Ratio (-0.749) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 88 (best 1 - 100 worst), indicating slightly worse than average price growth. ENGN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ENGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement